The Shrkeli article from last year. He predicted NKTR-118 would fail efficacy... it didn't. He presented data about Relistor from academic papers that he totally misinterpreted. He didn't foresee the CV problems associated with opioid antagonists. Conclusion, he has no f*ing clue.
NKTR is trading more than 10% higher than when he published his article. Case closed.